Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
After the FDA declared those shortages resolved in 2024 and 2025, mass compounding wound down, and compounding is now limited to patient-specific circumstances
This rigorous process ensures every article reflects current medical standards and is regularly updated to include the latest healthcare insights
We believe HRS9531 has the potential to make a meaningful difference in the lives of people living with obesity. The HRS9531 6 mg results further validate the potential of KAI-9531 to be a transformative therapy for patients living with obesity and overweight, and were excited to start our global Phase 3 program by year-end to evaluate both higher doses and longer treatment durations to unlock the full potential of KAI-9531, said Ron Renaud, President and Chief Executive Officer, Kailera
doi: 10.1111/acel.12075 196 HirschHAIliopoulosDStruhlK
Many patients starting GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) wonder about this potential side effect
We do not sell these single-nutrient products, so there is nothing to link
US$ 23.49
US$ 23.49
US$ 25.84
US$ 20.48
US$ 22.75
